Faze Three manufactures and exports home textile products like bathmats, rugs, and blankets, primarily serving large global retailers in the US and Europe.
The company possesses a narrow moat based on its status as a preferred vendor for major global retailers, supported by high switching costs and specialized manufacturing capacity. However, the low average net margin of 4.9% and ROCE of 10.9% suggest that this advantage does not translate into significant pricing power.
Management has reinvested over 300 crores since 2019 into capacity expansion and new product lines like patio mats. While revenue growth is strong, the low EPS CAGR of 1.2% indicates that recent capital deployment has yet to yield meaningful bottom-line efficiency.
The company's aggressive capacity expansion, funded by over 300 crores in reinvestment, failed to translate into earnings as operating leverage remained elusive. Despite strong revenue growth, the business was trapped in a low-margin commodity cycle where global retailers squeezed pricing, and rising input costs could not be passed through. The disconnect between a 20% revenue CAGR and a stagnant 1.2% EPS CAGR eventually led to a collapse in return on capital, while currency hedging losses and related-party entanglements eroded shareholder trust, causing the stock to de-rate toward its much lower intrinsic value.
RichFakir rates Faze Three Ltd's business quality as mediocre — 44/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Faze Three Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Faze Three Ltd is: Not rated. A mediocre business at an expensive price — it does not make our shortlist right now.
RichFakir's educational estimate of Faze Three Ltd's fair value is about ₹160 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →